CTOR vs ESPR

Citius Oncology, Inc. vs Esperion Therapeutics, Inc. — Valuation Comparison 2026

CTOR

Drug Manufacturers - Specialty & Generic
Citius Oncology, Inc.
Quality
3.4
out of 10
Value Trap
24
SAFE
Price
$0.81
Last close
Models
9/13
Active
VS

ESPR

Drug Manufacturers - Specialty & Generic
Esperion Therapeutics, Inc.
Quality
5.2
out of 10
Value Trap
30
LOW
Price
$3.13
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType CTOR Fair ValueCTOR Upside ESPR Fair ValueESPR Upside
Bayesian DCF Intrinsic $0.23 -70.9% $1.09 -65.0%
First Chicago Scenario $0.92 +11.3% $2.33 -25.7%
ML-RIV Intrinsic $0.08 -91.8% $0.97 -68.9%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CTOR vs ESPR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CTOR vs ESPR — Which Stock Is More Undervalued?

ESPR scores higher with a 5.2/10 quality rating vs CTOR's 3.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Citius Oncology, Inc. (CTOR) and Esperion Therapeutics, Inc. (ESPR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CTOR currently trades at $0.81 with a QOC of 3.4/10, while ESPR trades at $3.13 with a QOC of 5.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).